Next 10 |
2025-01-22 12:29:06 ET Summary Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today...
2025-01-16 16:18:33 ET Summary I initially rated Aurinia Pharmaceuticals a "Sell" in February 2024, but the stock has since risen over 25%, proving my call incorrect. Lupkynis, Aurinia's sole commercial product, showed inconsistent revenues and losses at first, but 2024 saw a turn...
2025-01-14 08:49:54 ET Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company’s ...
2024-12-08 13:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumat...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional scre...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024. Aurinia management will host one-on-one meetings with investors and will participate ...
2024-11-08 12:15:31 ET Summary Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance shee...
2024-11-07 14:24:01 ET More on Aurinia Pharma Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment Aurinia Pharmaceuticals: This Recovery Can Continue Aurinia Phar...
2024-11-07 11:44:10 ET Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Conference Call November 07, 2024, 08:30 ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
2025-01-14 08:49:54 ET Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company’s ...
2024-12-08 13:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumat...